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Introduction
Multiple sclerosis (MS) is a chronic immune-
mediated, demyelinating, and degenerative dis-
ease of the central nervous system (CNS) affecting 
about 2.8 million Worldwide.1 While the course 
of MS is highly variable, it is generally associated 
with chronic accelerated loss of CNS tissue and 
disability accrual.
Numerous disease-modifying treatments (DMT) 
have been licenced for people with MS (pwMS). 
However, access to DMT is highly regulated. In the 
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Abstract
Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak®) in multiple 
sclerosis (MS) patients.
Methods: Litak® was offered to MS-patients irrespective of disease course. Litak® 10 mg 
was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, patients 
received another 0–3 doses at week 5. A second course was administered 11 months later. 
Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-
peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-
of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light 
chain (NfL), and lymphocyte counts.
Results: In all, 208 patients received at least one course of treatment. Age at baseline was 
44 (17–72) years and EDSS 0–8.5. Cladribine was generally well tolerated. One myocardial 
infarction, one breast cancer, and three severe skin reactions occurred without long-term 
sequelae. Two patients died (one pneumonia, one encephalitis). Lymphopenia grade 3 
occurred in 5% and grade 4 in 0.5%. In 94 out of 116 pwMS with baseline and follow-up (BaFU) 
data after two treatment courses, EDSS remained stable or improved. At 18 months, 64% of 
patients with relapsing MS and BaFU data (n = 39) had NEDA. At 19 months, 62% of patients 
with progressive MS and BaFU data (n = 13) had NEPAD. Of n = 13 patients whose CSF-NfL 
at baseline was elevated, 77% were normalised within 12 months.
Conclusions: Litak® was well tolerated. Effectiveness in relapsing MS appeared similar to 
cladribine tablets and was encouraging in progressive MS. Our data suggest cladribine may be 
safe and effective in MS-patients irrespective of their disease stage.
Keywords: cladribine, disease-modifying treatment, multiple sclerosis, NEDA, NEPAD, 
treatment access
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United Kingdom (UK), DMT-eligibility is estab-
lished by the National Institute for Health and Care 
Excellence (NICE), Scottish Medicines Consortium 
and Belfast Health and Social Care Trust.
Cladribine tablets, CladT, were first licenced in 
Australia in 2010. However, CladT were sus-
pended less than 12 months after rejection of 
licence applications to the European Medicines 
Agency (EMA) and U.S. Food and Drug 
Administration in 2010/11.2 Key for these rejec-
tions were safety concerns related to lymphopenia 
and a potential risk of malignancies. However, 
independent research into the mechanism of action 
of cladribine in MS,3–5 the cancer risk6 and publica-
tion of further data from the pivotal studies5,7 sup-
ported a reappraisal and ultimately licencing of 
CladT (Mavenclad®) from August 2017. In the 
UK National Health Service (NHS), Mavenclad® 
was subsequently fast-tracked to become the first 
MS-DMT of the Accelerated Access Collaborative.8
We started using subcutaneously injected cladrib-
ine (Litak®), licenced for treatment of hairy-cell 
leukaemia since 1993,9 as an off-label immuno-
therapy from late 2014, that is, 3 years prior to 
EMA licencing of Mavenclad®. As part of our 
plans to make cladribine available to pwMS we 
confirmed, in a meeting with the UK Medicines 
and Healthcare Regulatory Authority on 18 April 
2013, the bioequivalence of parenteral and oral 
cladribine. Dosing, however, had to be adjusted 
to 100% bioavailability of parenteral cladribine 
compared to about 42% of CladT.10 We previ-
ously described preliminary findings in our 
emerging cohort of pwMS undergoing Litak® 
treatment.9 Here, we report on a significantly 
expanded cohort including new information on 
the risks and potential benefits of this treatment.
Methods
This service development was registered with the 
Clinical Effectiveness Unit at Barts Health NHS 
Trust (Barts Health; registration number: 11483). 
The use of Litak® in pwMS was approved by the 
Barts Health Neuroscience Clinical Network.
From October 2014, pwMS were offered Litak® 
irrespective of whether they were eligible for NHS 
DMT. Patients considering the treatment were 
provided with comprehensive information to aid 
their understanding and decision regarding Litak® 
treatment.11
Between October 2014 and February 2016, treat-
ment decisions were largely based on clinical 
judgement (chronic disability accrual, relapses) 
although gadolinium-enhancing (Gd +) lesion(s) 
and new/enlarging T2 lesion(s) on MRI were con-
sidered. From February 2016 onwards disease 
activity based on MRI and/or cerebro-spinal fluid 
(CSF) neurofilament light chain (NfL) levels, 
over and above clinical activity, was mandatory 
for treatment eligibility.12 Treatment with Litak® 
in all cases was approved by the neuroinflamma-
tion multidisciplinary team of Barts Health.
Safety review
Prior to treatment initiation, pwMS had to pass a 
safety checklist11 including blood tests (full blood 
and differential white cell counts, biochemistry, 
liver function tests, creatinine) and urinalysis. 
The presence of active and/or latent infections 
was ruled out, and the absence of other contrain-
dications, as per Litak® SmPC confirmed. 
Minimum lymphocyte count (TLC) had to be 
1.0 × 109 L−1. Active malignancies were excluded 
based on history and clinical examination. 
Compliance with regular cervical cancer screen-
ing was mandatory.
In patients without immunoreactivity against 
Varicella zoster virus, vaccination was mandatory. 
We also recommended concomitant famciclovir 
500 mg twice daily as a herpes prophylaxis for 
60 days from the first Litak® administration. 
Reassured that very few cases developed signifi-
cant lymphocyte toxicity, the dose of famciclovir 
was reduced to 250 mg per day. We discontinued 
antiviral prophylaxis after Mavenclad® was licenced 
in August 2017.
Patients of childbearing potential had to use effec-
tive contraception during treatment, and for at 
least 6 months after receiving the last dose of 
Litak®. Due to the potential impact of cladribine 
on male fertility as per Litak® SmPC,13 men were 
offered cryopreservation of sperm.
Informed consent was documented using a form 
designed in 2015, revised in 2016 and 2018.11
Treatment
The Litak® dose administered to each patient was 
personalised to body weight and total lymphocyte 
count (TLC) as previously described.9,14 In short, 
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Litak® 10 mg was administered on three consecu-
tive days (four if body weight was >90 kg). Based 
on TLC at week 4, another 0–3 injections were 
given in week 5 (Figure 1). The treatment course 
was repeated in weeks 48 and 52, again depend-
ing on weight and TLC.
Outcomes
Patients were clinically assessed at baseline and 
annually thereafter, though some were seen more 
frequently. Relapse and expanded disability sta-
tus scale (EDSS)15 data were extracted from the 
electronic health record at the point of care. From 
September 2016, we introduced the nine-hole-
peg (9HPT) and Timed-25-foot-walking 
(T25FW) tests as additional assessments.16 
Follow-up included adverse events (AEs), pres-
ence/absence of Gd+ lesions on T1-weighted MRI 
and new lesion(s), or an increased lesion size, 
compared to a reference scan on T2-weighted 
MRI. CSF-NfL levels were quantified using a 
commercial ELISA (UmanDiagnostics NF-Light 
ELISA).17 The upper limit of normal (ULN) of 
the CSF-NfL level was 290 pg/mL for patients 
aged <30 years, 380 pg/mL for 31–39 year olds, 
and 830 pg/mL for patients ⩾40 years.18
Disability progression was defined as an increase 
in EDSS between two assessments of (1) ⩾1 
point if baseline EDSS was ⩽5.5 and (2) ⩾0.5 
point if baseline EDSS was ⩾6.0. Cut-offs of 
20% change (speed) were used for both T25FW 
and 9HPT.19 The proportion of patients with ‘no 
evidence of disease activity’ (NEDA) and ‘no evi-
dence of progression or active disease’ (NEPAD) 
were calculated for patients with complete data-
sets. Since a number of patients in our cohort 
were unable to complete the T25FW, the test was 
dropped to create a measure called NEPAD∗. 
Figure 2 illustrates the process of selecting suita-
ble patients with complete datasets. NEDA was 
Figure 1. Dosing schedule of Litak® adjusted to body weight and lymphocyte count. Treatment course 1: 
Following injections of Litak® 10 mg on 3–4 consecutive days in week 1, total lymphocyte count (TLC) was 
measured at week 4. If TLC was ⩾1.0 × 109 L−1, further injections of Litak® 10 mg were given on three 
consecutive days in week 5. If TLC was 0.8–0.9 × 109 L−1, further injections of Litak® 10 mg were given on 
two consecutive days in week 5. If TLC was 0.5–0.7 × 109 L−1, one further injection of Litak® 10 mg was given 
in week 5. If TLC was <0.5 × 109 L−1, no further injection of Litak® was given during this treatment course. 
Treatment course 2 A: If TLC at week 44 was ⩾1.0 × 109 L−1, injections of Litak® 10 mg were given on three 
consecutive days in week 48. TLC was then measured at week 51. If TLC was ⩾1.0 × 109 L−1, further injections 
of Litak® 10 mg were given on three consecutive days in week 52. If TLC was 0.8–0.9 × 109 L−1, further 
injections of Litak® 10 mg were given on two consecutive days in week 52. If TLC was 0.5–0.7 × 109 L−1, one 
further injection of Litak® 10 mg was given in week 52. If TLC was <0.5 × 109 L−1, no further injection of Litak® 
was given. Treatment course 2B: If TLC at week 44 was 0.8–0.9, injections of Litak® 10 mg were given on two 
consecutive days in week 48. If TLC was 0.5–0.7 × 109 L−1, one further injection of Litak® 10 mg was given in 
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defined as no evidence of disability progression 
measured using the EDSS, absence of relapses 
and of MRI activity. NEPAD was defined as no 
evidence of disability progression measured using 
EDSS, absence of progression on T25FW and 
9HPT and absence of both relapses and MRI 
activity. NEPAD* was defined as NEPAD disre-
garding the T25FW.
Statistical analysis
Descriptive statistics are reported as mean/median 
(range) for continuous variables and as frequen-
cies (%) for categorical variables. Safety and 
para-/clinical efficacy after two treatment courses 
was compared to baseline. The analysis was per-
formed using Stata 16.
Results
Between October 2014 and November 2018, a 
total of 208 pwMS (131 females, 77 males) 
received at least one course of Litak® (Table 1); 
196 patients (94%) completed two courses. See 
Table 1 for demographic and clinical characteris-
tics. Age at baseline was 44 years (mean; range: 
17–72 years). Disease duration was 11 years 
(mean; range: 1–48 years). One-hundred patients 
had relapsing (RMS) and 108 progressive (PMS) 
disease. Of those with PMS, 62 had SPMS and 
Figure 2. CONSORT flow diagram showing patient selection for No Evidence of Disease Activity (NEDA), No 
Evidence of Progression or Active Disease (NEPAD) and NEPAD less the Timed 25 foot Walking Test (NEPAD*) 
analysis based on criteria for data completeness.
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46 PPMS. EDSS was 5.5 (median: 0–8.5). One-
hundred-and-thirteen patients were eligible for 
NHS DMT, but chose Litak® instead. Ninety-
five patients were not eligible for NHS DMT. 
The cohort includes seven patients previously 
reported as case studies.12,20–22
Ninety-two patients (44%) were DMT naive; 
116 (56%) received at least one licenced or off-
label immunotherapy prior to Litak® treatment; 
52 patients (26%) received one, 50 (24%) two, 
10 (5%) three, and 4 (2%) four drug(s) prior to 
commencing Litak®. Of patients receiving DMT 
prior to Litak® treatment, 66 had RMS and 50 
PMS. The last DMTs patients received prior to 
starting Litak® are listed in Table 2. The most 
common prior DMTs were dimethyl fumarate, 
fingolimod and beta interferons; 51 out of 116 
(44%) patients started treatment with Litak® due 
to evidence of disease activity and/or clinical 
deterioration. This was based on MRI only in 13 
(11%), relapses in 12 (10%), and clinical pro-
gression in 21 (18%); in three patients, no details 
of disease progression were documented. In three 
patients, both disease progression and MRI 
activity were detected. One patient had a relapse 
and detectable MRI activity, one switched from 
dimethyl fumarate due to MRI activity and prob-
lems with taking a daily tablet. One out of 116 
pwMS received CladT 3.5 mg/kg over 2 years 
during both the CLARITY and CLARITY 
extension trials (total dose 7 mg/kg).23 She then 
went onto interferon β-1a (Avonex®), 54 months 
after completing her second full treatment cycle 
with CladT. Due to MRI activity, she started 
Litak® after 7 months of Avonex® treatment.
Table 1. Baseline demographics and clinical characteristics of 208 patients with multiple sclerosis treated with 
Litak®. Results are shown for the whole cohort and separately for relapsing MS (RMS) and progressive MS (PMS).
Disease course (n) All (208) RMS (100) PMS (108)
Female/ male (n) 131/77 73/27 58/50
Mean age (years (range)) 44 (17–72) 40 (17–70) 48 (21–72)
Mean disease duration (years (range)) 11 (1–48) 9 (1–28) 13 (2–48)
Number of prior DMT/ immunotherapies (n)
 0/None 92 34 58
 1 52 23 29
 2 50 33 17
 3 10 6 4
 4 4 4 0
Median EDSS (range) 5.5 (0–8.5) 3.25 (0–7.5) 6 (1–8.5)
Active MRIa (n/total (%)) 91/187 (48.6) 49/92 (53.3) 42/95 (44.2)
⩾ 1 Gd+ lesion/s (n/total (%)) 45/172 (26.2) 23/82 (28) 22/90 (24.4)
Elevated CSF-NfL (n/total (%)) 34/84 (40.5) 13/27 (48) 21/57 (36.8)
DMT, disease-modifying treatments; EDSS, expanded disability status scale; PMS, progressive; RMS, relapsing.
aActive MRI was defined as MRI head showing at least one Gadolinium-DTPA positive (Gd +) lesion on T1 weighted and/or 
new lesion/s on T2 weighted MRI head compared to a reference scan acquired 4.6 months (median; IQR 2.4, 7.8) previously. 
Baseline MRI data were unknown in n = 9 patients. In 21 patients (8 relapsing and 13 progressive MS) baseline MRI was 
not available. Of 42 pwPMS with baseline MRI activity, 39 had recorded relapse documentation. Of these 39, 4 pwPMS each 
had one relapse during the 12 months prior to starting cladribine. Gd was not administered in 14 patients (9 relapsing and 
5 progressive MS). In one patient with relapsing MS Gd was administered but the MRI examination was terminated early. 
Disease duration was calculated from onset of the first symptom and was unknown in 17 patients (3 relapsing and 14 
progressive MS). Baseline EDSS data were missing in 22 patients.
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In all, 65 out of 116 pwMS (56%) went on 
treatment with Litak® due to AEs, risk consid-
erations of their current immunotherapy, or 
other reasons. Four patients had previously 
been treated with off-label immunotherapies 
(two mitoxantrone and one each cyclophospha-
mide and azathioprine). Six patients had been 
participating in clinical trials for PMS and were 
left without immunotherapy; two each partici-
pated in the ASCEND study of natalizumab in 
secondary progressive (SP) MS,24 the 
INFORMS trial of fingolimod20,25 in primary 
progressive (PPMS) and the Arpeggio trial of 
laquinimod in PPMS.26
One patient felt they had no benefit from taking 
dimethyl fumarate; one had been treated with 
interferon beta until diagnosis of SPMS and was 
left without immunotherapy; one was on fingoli-
mod and considered at high risk of progressive 
multifocal leukoencephalopathy (PML); one had 
extended travel plans and switched within 4 weeks 
from natalizumab to Litak® to avoid monthly infu-
sions. Two patients developed anti-natalizumab 
antibodies. In two cases, no reasons were 
documented.
The reasons why 12 pwMS (6%) did not receive 
a second course of Litak® included personal 
choice in five and one each of difficulty travelling 
to our centre, switch to haematopoietic stem cell 
transplantation (HSCT) and switch to fingoli-
mod due to relapse. Two of 208 patients deferred 
their second course due to planned pregnancy. 
One patient died prior to receiving their second 
course. One patient did not receive their second 
course due to ongoing lymphopenia (0.4 × 109 
L−1). Notably, this patient underwent chemother-
apy for Hodgkin’s lymphoma 28 years prior to 
starting Litak®. Moreover, Litak® was preceded 
by dimethyl fumarate treatment for 22 months, 
which was associated with lymphopenia. Her 
most recent TLC, 37 months after her single 
course of Litak®, was 0.9 × 109 L−1.
Table 2. Overview of the last immunotherapy received prior to Litak® in 116 patients with multiple sclerosis.
Immunotherapy 





Time between stopping prior 
immunotherapy and starting 
Litak® (median, months (IQR))
Dimethyl fumarate 38 (32.8) 13.3 (4.7, 22.4) 5.4 (2.7, 16.6)
Fingolimod 27 (23.3) 24 (17.3, 38.5) 2.9 (2.1, 7.5)
Interferon β-1a (Avonex®), 
IFN β-1a (Rebif®) & 
Interferon β-1b (Betaferon®)
15 (12.9) 72 (13.1, 84.1) 24 (8.3, 49.9)
Natalizumab 13 (11.2) 12 (7, 24) 10.9 (2.5, 28.6)
Glatiramer acetate 9 (7.8) 36 (2.5, 82.2) 2.6 (2.1, 12.8)
Mitoxantrone 4 (3.4) 13.5 (12.8, 14.2) 60.4 (46.9, 90.6)
Azathioprine 3 (2.6) 12.5 (6.8, 18.2) 79.4 (64.8, 79.6)
Alemtuzumab 2 (1.7) 30 (21, 39) 6 (3.1, 8.8)
Laquinimod 2 (1.7) 6 (3.4, 8.5) 12.8 (8.8, 16.8)
Cyclophosphamide 1 (0.9) 8 (8, 8) 31.2 (31.2, 31.2)
Methotrexate 1 (0.9) 75 (75, 75) 0.6 (0.6, 0.6)
Teriflunomide 1 (0.9) 1.4 (1.4, 1.4) 14.8 (14.8, 14.8)
IQR, interquartile range.
aTreatment duration in eight patients is unknown. Six/8 patients started and stopped immunotherapy within one year; their 
exact treatment duration is unknown.
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Of the 187 patients who had an MRI-head prior 
to their first cladribine injection, 91 (49%) dis-
played activity (Table 1).
Since our dosing schedule was adapted to both 
body weight and individual total lymphocyte 
count (TLC), only 75% received the maximum 
dose (60–70 mg) at their first course while 25% 
received a reduced dose based on TLC (Figure 
1). Of 208 patients treated, 28 (14%) weighed 
>90 kg and thus received 40 mg (rather than 30 
mg in pwMS ⩽90 kg) during week 1 of their first 
treatment course. Of these 28 patients, 18 
received 70 mg in total during their first course. 
Of 196 pwMS receiving a second course of Litak®, 
35% received the full dose (60–70mg) while in 
65% the dose was reduced based on their TLC 
(Figures 3A and 3B).
Safety and tolerability
See Table 3 for a summary of AEs. Overall, Litak® 
was well tolerated.
However, two patients died. The first patient was 
admitted to a different hospital. He was 61 years 
old and diagnosed with MS 16 years before start-
ing Litak®. He died with an EDSS of 6.5, 44 
weeks after completing his second course of 
Litak®. The death certificate stated ‘encephalitis’. 
No microorganism was identified and no autopsy 
performed.
The second patient died from H1N1 influenza-
associated pneumonia, as reported previously.22 
This 53-year-old woman had an EDSS of 8.5 and 
died 11 weeks after completing her first course of 
Litak®. Of note, her TLC was within normal 
range (1.1 × 109 L−1) 4 weeks after completing 
the course, but was then admitted at the begin-
ning of week 11 with pneumonia and grade 4 
lymphopenia22; she died shortly after.
One case of grade 3 invasive ductal carcinoma/
high-grade ductal carcinoma in situ occurred 
(lymph node negative/HER2-negative/
ER-positive), 10 months after completing the sec-
ond course of Litak®. Breast lumpectomy fol-
lowed by radiotherapy was undertaken. The 
patient’s oncotype Recurrence Score was 23. No 
chemotherapy was given. She has fully recovered 
with no evidence of malignancy on two annual 
follow-up mammograms and remains on treat-
ment with tamoxifen.
As reported previously,9,21 one patient suffered a 
myocardial infarction 6 weeks after starting Litak® 
and three developed a severe allergic skin reaction 
(SASR) with complete resolution within weeks 
on steroids and antihistamines.
Figure 3. (a) Proportion of patients receiving the maximum and reduced dose of Litak® at courses 1 and 2. (b) Total dose of Litak® 
administered at courses 1 and 2.
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Table 3. Overview of adverse events in a cohort of 208 patients with multiple sclerosis.
System Adverse event N
Gastrointestinal (1%) Nausea 1
Diarrhoea 1
Colitis 1







Skin (6%) Shingles 5
Alopecia 1
Rash 6
Cardiovascular (0.5%) ST-elevation myocardial infarction 1
Infections & immunity (10%) Aspiration pneumonia & H1N1 (deceased) 1
Abnormal smear 3





Metabolic (1%) Thyroid disorder 2
Irregular menstruation 1
Others (3%) Neck of femur fracture 1
Mild allergic reaction 1
Pregnancy 2
Acute kidney injury 1
Anaemia 1
Malignancy (0.5%) Breast cancer 1
CNS, central nervous system; MS, multiple sclerosis.
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Lymphocyte kinetics
Of 208, 34 (16%) did not have any lymphopenia 
in the course of Litak® treatment (Figure 4). 
Grades 1 and 2 lymphopenia occurred in 49 
(24%) and 113 (54%), respectively. Grade 3 
lymphopenia occurred in 11 (5%): 3 patients at 
weeks 4, 2 patients at week 20, and in one patient 
each at weeks 32, 44, 51, 56, 68, and 92. Grade 
4 lymphopenia was detected in the patient 
described above who died of  influenza-associated 
pneumonia.
Clinical effectiveness
The clinical outcomes are summarised in Table 4 
and Figure 5. Median EDSS after a mean follow-
up of 17 months increased from 5.0 to 5.5. Of 
116 patients where EDSS scores were available at 
two time points, 94 (81%) were stable or 
improved, while 22 out of 116 (19%) deterio-
rated. In 130 patients where relapse data were 
available at two time points, eight patients (6%) 
relapsed. The mean MRI follow-up period was 
19 months. In 121 of 147 patients (82%) with 
MRI head data at two time points available, no T2 
or Gd+ lesion activity was detected at follow-up.
In 27 of 100 patients with RMS, 9HPT measure-
ments were obtained at baseline and follow-up 
(median 13 months; range: 12–14). Dominant 
hand 9HPT times at baseline and follow-up were 
18.0 and 18.9 s, respectively. Nondominant 
9HPT times at baseline and follow-up were 20.9 
and 20.2 s, respectively. Median T25FW times at 
baseline and follow-up (median 13 months; 
range: 12–14) were 4.9 and 4.1 s (n = 24).
In 31 out of 108 patients with PMS, 9HPT meas-
urements were obtained at baseline and follow-up 
(median 13 months; range: 12–14). Dominant 
hand 9HPT times at baseline and follow-up were 
25.0 and 26.3 s, respectively (n = 30). 
Nondominant 9HPT times at baseline and fol-
low-up were 34.0 and 34.5 s, respectively 
(n = 31). Median T25FW times at baseline and 
follow-up (median 13 months; range: 12–16) 
were 7.6 and 6.8 s (n = 15).
NEDA, NEPAD, and NEPAD*
The proportion of patients with RMS having 
NEDA (total n = 39) at 18 months (median; 
range: 16–22) was 64% (95% CI: 47%, 79%; 
Figure 5). The proportion of patients with PMS 
(pwPMS) achieving NEPAD (total n = 13) at 19 
months (median; range: 15–25) was 62% (95% 
CI: 32%, 86%). The proportion of pwPMS 
achieving NEPAD∗ (total n = 16) was 56% 
(95% CI: 30%, 80%).
Neurofilament light chain level in the  
cerebro-spinal fluid
In 23 out of 208 pwMS (n = 8 pwRMS and 15 
pwPMS), CSF-NfL results were obtained before 
and after treatment. In pwRMS, CSF was 
obtained at least 3 months after their last docu-
mented relapse in all but one case.27 Baseline 
lumbar punctures were performed 48 days 
(median; IQR: 12, 178) prior to starting treat-
ment. Follow-up CSF was collected 311 days 
(median; IQR: 311, 357) after treatment initia-
tion. Thus, 19 of 23 patients had one course, and 
Figure 4. Total lymphocyte count (TLC) in patients treated with Litak® dose-adapted to body weight and TLC.
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3 of 23 two courses of Litak® completed at the 
time follow-up CSF was collected. One patient 
had their follow-up LP between weeks 1 and 5 of 
their second treatment course.
CSF-NfL levels in the current cohort were 652 pg/
mL (mean; IQR: 458–1063) and 334 pg/mL (mean; 
IQR: 186–505) at baseline and follow-up, respec-
tively (p < 0.01; Wilcoxon signed rank test). Of the 
13 out of 23 pwMS whose CSF-NfL was above 
ULN at baseline, 10 had normal levels at follow-up 
(Figure 6). In all three patients where CSF-NfL did 
not fall below their age-adjusted ULN (see below), 
NfL nevertheless dropped significantly in two of 
three from extremely high baseline levels (by 73% 
and 80%), after a single course of Litak®.12
Discussion
Whilst the availability of highly effective DMT has 
significantly improved for patients with RMS,28 
access to treatment for many pwMS remains lim-
ited, including patients with PMS and an EDSS of 
⩾6.5.14 Using Litak® off-label enabled treatment 
decisions based on the biology of MS as an 
immune-mediated disease throughout its course,29 
rather than cost-effectiveness criteria forming the 
basis of DMT eligibility. In particular, providing 
Litak® on a compassionate basis enabled the col-
lection of preliminary data on the feasibility, 
safety, and potential effectiveness of a potent 
immunotherapy in people with advanced PMS. 
To identify treatments for this cohort of patients is 
among the top priorities of MS charities 
Worldwide.30,31
Following on from our early experience with 
Litak®,9 we have now gathered data in a relatively 
large cohort of MS patients across the disease 
spectrum, heterogeneous in terms of age, disease 
course and duration, disability level, and prior 
interventions. The majority (n = 116) moved 
Table 4. Clinical outcomes in patients with multiple sclerosis treated with Litak®.
Outcome Baseline Follow-up
All RMS PMS All RMS PMS
Median EDSS (total n = 116; n pwRMS = 58, n pwPMS = 58) 5.0 3.0 6.0 5.5 3.0 6.5
Stable or improved (%) 94 (81) 55 (95) 39 (67)
Deteriorated (%) 22 (19) 3 (5) 19 (33)
T25FW (total n = 39; n pwRMS = 24, n pwPMS = 15) 
(average time, seconds)
6.3 4.9 7.6 5.55 4.1 6.8
9HPT (total n = 57 dominant (n pwRMS = 27, n 
pwPMS = 30), n = 58 nondominant (n pwRMS = 27, n 
pwPMS = 31))
 
Dominant (average time, seconds) 21.5 18.0 25.0 21.7 18.9 26.3
Nondominant (average time, seconds) 23.7 20.9 34.0 23.5 20.2 34.5
Relapses (total n = 130; n pwRMS = 61, n pwPMS = 69)  
Patients (%) 36 (28) 27 (44) 9 (13) 8 (6) 6 (10) 2 (3)
MRI (total n = 147; n pwRMS = 77, n pwPMS = 70)  
Gd + and/or new T2 lesions (%) 71 (48) 37 (48) 34 (49) 26 (18) 19 (25) 7 (10)
No new lesions (%) 76 (52) 40 (52) 36 (51) 121 (82) 58 (75) 63 (90)
EDSS, expanded disability status scale; 9HPT, Nine-hole-peg-test; T25FW, Timed 25 foot walking-test, MRI, Magnetic resonance imaging; PMS, 
progressive multiple sclerosis; RMS, relapsing multiple sclerosis.
Outcomes at baseline and follow-up for patients with data at both timepoints available. EDSS and relapse follow-up period was 17 months (mean; 
range 14–21); MRI follow-up period of 19 months (mean; range: 16–23). Nine-hole-peg test follow-up period was 13 months (mean; range 12–14). 
Timed-25-foot-walking test follow-up period was 13 months (mean; range: 12–16).
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from a different immunotherapy to Litak®. In 77 
of 116 patients (66%), transition to treatment 
with Litak® commenced within less than 6 months 
(Table 2), a time lapse short enough to be consid-
ered a ‘switch’ period between immunotherapies.
Two of our patients died in the context of receiv-
ing Litak®. In both cases, a causal relationship 
remains uncertain. While the treatment may have 
contributed to the risk of contracting H1N1 influ-
enza in patient 1, TLC was within normal range 7 
weeks before the patient’s rapid decline and 
death. Unfortunately, we were unable to obtain 
more detailed information about patient 2 who 
reportedly died with encephalitis of unknown 
cause, 44 weeks after completing his second 
course of Litak®.
Skin-related AEs, including shingles, were seen in 
6%, including three previously reported cases of 
SASR.21 A recent report on 239 pwMS treated 
with CladT detailed further skin reactions, and 
an overall incidence of 32%,32 such that we con-
clude Litak® does not harbour a higher risk of 
Figure 5. Composite measures indicating effectiveness of Litak® in patients with relapsing and progressive 
multiple sclerosis. (a) Venn diagrams representing the proportion of patients achieving No Evidence of Disease 
Activity (NEDA), (b) No Evidence of Progression or Active Disease (NEPAD), and (c) NEPAD excluding the 
Timed-25-foot-Walking-Test (NEPAD*). CI, confidence interval.
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skin pathologies than the licenced oral compound 
or indeed other highly effective immunotherapies 
used in MS.33 Other AEs were rare. Of note, 
headaches were uncommon. While the phase III 
CLARITY trial of CladT in pwRMS reported 
headache in 21–24% (placebo: 17%),23 head 
pains were detected in less than 3% in our cohort.
The large majority of pwMS underwent two 
courses of Litak®. Adjustment of the dose admin-
istered not only to body weight but also to indi-
vidual TLC had the expected effect of reducing 
the number of patients with severe (grade 3) lym-
phopenia to 5%. Our safety-driven approach led 
to dose-adjustments based on low TLC in 25% 
during course 1 and 65% during course 2, with 
variable dose reductions.
We and others have previously suggested that 
depletion of memory B cells is crucial for effec-
tive disease control in pwMS.3,34 Evidence sug-
gests that a single course of Litak® leads to 
significant and long-term depletion of B-cell 
subsets, particularly memory B cells, for at least 
12 months.4 Very similar results have recently 
been reported in patients with RMS treated 
with CladT35 in the context of the 
MAGNIFY-MS study (NCT04783935). Of 
note, ongoing depletion of memory B cells 
occurred while other, particularly naive B-cell 
subsets, either normalised or exceeded their 
baseline level.4,35
We therefore expect that memory B cells remain 
depleted for at least 12 months after dosing with 
either parenteral4 or oral35,36 cladribine. Further 
follow-up studies, including T-cell subsets, are 
underway to confirm (or reject) this hypothesis. 
However, follow-up data from a cohort receiving 
only a single course of CladT suggest that even 
half of the licenced dose bears significant effec-
tiveness. An observational cohort of 90 pwRMS 
with a baseline median EDSS of 5.25 receiving 
one course of CladT remained stable on the 
EDSS for 2 years in 80% of cases.37
The proportion of patients with RMS achieving 
NEDA following treatment with Litak® presented 
here is similar to the rate reported with CladT.38 
Our results also map onto findings in a recent 
Real World Evidence (RWE) cohort of n = 65 
pwMS treated with either i.v. or oral cladribine.39 
Although comparison of results is limited since 
the authors of that study did not distinguish 
between RMS and PMS in their analysis of 
NEDA, the total cladribine dose administered 
and, in those treated with the i.v. preparation, 
adjustment to TLC indicates a similar therapeu-
tic approach to ours.39
The NEPAD rate in our cohort of PMS was in line 
with earlier evidence suggesting Litak® as a prom-
ising immunotherapy not only in RMS but also 
PMS.12,20,39,40 In order to include pwMS unable to 
complete the T25FW, we introduced NEPAD∗ 
removing the walking assessment. Both NEPAD 
and NEPAD∗ data suggest a positive effect of 
Litak® in more than half of the patients with avail-
able baseline and follow-up data (Figure 5(b) and 
(c)). However, the number of patients with full 
follow-up datasets is small, and conclusions regard-
ing efficacy in this cohort should therefore be made 
with caution. Moreover, sensitivity analysis 
revealed that patients with higher EDSS scores 
were more likely lost to follow-up (Supplementary 
Table 1) thereby introducing bias. Having said 
that, we did not detect significant differences in 
characteristics of pwRMS who had complete data-
sets to calculate NEDA versus those without 
(Supplementary Table 2).
Common reasons for limited follow-up data in 
RWE cohorts also applied to our dataset: (1) MRI 
was performed as part of routine care provision. 
Figure 6. Cerebro-spinal fluid neurofilament light chain (CSF-NfL) levels in 
23 patients with MS before and after treatment with Litak®.
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While acquisition protocols were not standardised 
across referring sites, they all included sequences 
routinely used in the care of patients with MS. 
Efforts are currently being undertaken to homog-
enise MRI protocols for pwMS across the UK.41,42 
(2) Time constraints precluding collection of a 
hands-on EDSS during routine NHS appoint-
ments. Although not used in the current cohort, 
we recently started using a web-based version of 
the EDSS,43 which we expect will lead to a more 
complete dataset at the next cut-off. (3) Phased 
introduction of systematic 9HPT and T25FW 
data collection only since late 201616 limiting the 
number of data points available for NEPAD/
NEPAD∗. While no firm conclusions can there-
fore be drawn, our data9,14 underpinned the case 
for a placebo-controlled, multicentre trial of 
CladT in PMS and an EDSS of 6.5-8.5, which is 
now underway.44 Our off-label cohort will remain 
under long-term follow-up including clinical deci-
sion-making regarding further DMT following 
two courses of Litak® treatment.
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